Clinical Trial Update: Open Label Study of R788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP) [Phase 3]

View source ↗

Summary

Open-label Phase 3 trial investigating R788 for persistent/chronic immune thrombocytopenic purpura (ITP) has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immune Thrombocytopenic Purpura

Drugs mentioned

• R788

Snippet

Sponsor: Rigel Pharmaceuticals | Conditions: Immune Thrombocytopenic Purpura | Phase 3 | Status: COMPLETED | Results posted: 2023-12-11